Alzheimer's disease as a synaptopathy: Evidence for dysfunction of synapses during disease progression

被引:49
|
作者
Meftah, Soraya [1 ,2 ]
Gan, Jian [1 ,2 ]
机构
[1] Univ Edinburgh, UK Dementia Res Inst, Edinburgh, Scotland
[2] Univ Edinburgh, Ctr Discovery Brain Sci, Edinburgh, Scotland
来源
基金
英国医学研究理事会;
关键词
synapse; dysfunction; electrophysiology; oscillations; amyloid; tau; Alzheimer's disease; synaptic transmission; MILD COGNITIVE IMPAIRMENT; CA1 PYRAMIDAL NEURONS; LONG-TERM POTENTIATION; RTG4510 MOUSE MODEL; AMYLOID-BETA; SYNAPTIC PLASTICITY; A-BETA; APOLIPOPROTEIN-E; ENDOGENOUS TAU; NMDA RECEPTORS;
D O I
10.3389/fnsyn.2023.1129036
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The synapse has consistently been considered a vulnerable and critical target within Alzheimer's disease, and synapse loss is, to date, one of the main biological correlates of cognitive decline within Alzheimer's disease. This occurs prior to neuronal loss with ample evidence that synaptic dysfunction precedes this, in support of the idea that synaptic failure is a crucial stage within disease pathogenesis. The two main pathological hallmarks of Alzheimer's disease, abnormal aggregates of amyloid or tau proteins, have had demonstrable effects on synaptic physiology in animal and cellular models of Alzheimer's disease. There is also growing evidence that these two proteins may have a synergistic effect on neurophysiological dysfunction. Here, we review some of the main findings of synaptic alterations in Alzheimer's disease, and what we know from Alzheimer's disease animal and cellular models. First, we briefly summarize some of the human evidence to suggest that synapses are altered, including how this relates to network activity. Subsequently, animal and cellular models of Alzheimer's disease are considered, highlighting mouse models of amyloid and tau pathology and the role these proteins may play in synaptic dysfunction, either in isolation or examining how the two pathologies may interact in dysfunction. This specifically focuses on neurophysiological function and dysfunction observed within these animal models, typically measured using electrophysiology or calcium imaging. Following synaptic dysfunction and loss, it would be impossible to imagine that this would not alter oscillatory activity within the brain. Therefore, this review also discusses how this may underpin some of the aberrant oscillatory patterns seen in animal models of Alzheimer's disease and human patients. Finally, an overview of some key directions and considerations in the field of synaptic dysfunction in Alzheimer's disease is covered. This includes current therapeutics that are targeted specifically at synaptic dysfunction, but also methods that modulate activity to rescue aberrant oscillatory patterns. Other important future avenues of note in this field include the role of non-neuronal cell types such as astrocytes and microglia, and mechanisms of dysfunction independent of amyloid and tau in Alzheimer's disease. The synapse will certainly continue to be an important target within Alzheimer's disease for the foreseeable future.
引用
收藏
页数:19
相关论文
共 50 条
  • [41] Predicting progression of Alzheimer's disease
    Doody, R
    Pavlik, V
    Massman, P
    Rountree, SS
    Darby, E
    Chan, W
    NEUROLOGY, 2006, 66 (05) : A347 - A347
  • [42] Progression of atrophy in Alzheimer's disease
    Killiany, Ronald
    LANCET NEUROLOGY, 2006, 5 (10): : 805 - 806
  • [43] Slowing progression of Alzheimer's disease
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (02) : 185 - 185
  • [44] Metabolome in progression to Alzheimer's disease
    Oresic, M.
    Hyotylainen, T.
    Herukka, S-K
    Sysi-Aho, M.
    Mattila, I.
    Seppanan-Laakso, T.
    Julkunen, V.
    Gopalacharyulu, P. V.
    Hallikainen, M.
    Koikkalainen, J.
    Kivipelto, M.
    Helisalmi, S.
    Lotjonen, J.
    Soininen, H.
    TRANSLATIONAL PSYCHIATRY, 2011, 1 : e57 - e57
  • [45] Slowing the progression of Alzheimer's disease
    Laffman, Elise
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (05) : 656 - 656
  • [46] Halting the progression of Alzheimer's disease
    Houlton, S
    MANUFACTURING CHEMIST, 2001, 72 (09): : 18 - 20
  • [47] Predicting progression of Alzheimer's disease
    Doody, Rachelle S.
    Pavlik, Valory
    Massman, Paul
    Rountree, Susan
    Darby, Eveleen
    Chan, Wenyaw
    ALZHEIMERS RESEARCH & THERAPY, 2010, 2 (01):
  • [48] Synapses, synaptic activity and intraneuronal Aβ in Alzheimer's disease
    Tampellini, Davide
    Gouras, Gunnar K.
    FRONTIERS IN AGING NEUROSCIENCE, 2010, 2
  • [49] Alzheimer's Disease: Effects on brain circuits and synapses
    Ch'ng, Toh Hean
    Augustine, George J.
    SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2023, 139 : 1 - 2
  • [50] ROCK, PAK, and Toll of synapses in Alzheimer's disease
    Salminen, Antero
    Suuronen, Tiina
    Kaarniranta, Kai
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 371 (04) : 587 - 590